FDA Grants Fast Track Designation to CERC-002 for Treatment of Hospitalized Patients with ...

Retrieved on: 2021-05-11 11:03:45

Tags for this article:

Click the tags to see associated articles and topics

FDA Grants Fast Track Designation to CERC-002 for Treatment of Hospitalized Patients with .... View article details on hiswai:

Excerpt

CERC-002 is a first-in-class fully human monoclonal antibody targeting LIGHT (tumor necrosis factor superfamily member 14, TNFSF14). Fast Track ...

Article found on: www.biospace.com